

JOB RESULTS

Job Details

Analysis date: 2023-07-31 - 10:44 am

Job name: **Demo**

Total samples: 9

Internal ID: 1012-6796-3642-890

Job Status: Completed



Part 1 - Job overview

Name: **Demo** Analysis date: **2023-07-31** 10:44

Product: HIV (Sanger)

Job status: Completed

Sequencing platform: CE Job ID: 1012-6796-3642-890

Samples: 9
Controls: 2

Assay: Thermo Fisher (with Integrase)

1.1 - Samples overview

	Sample name	Exatype sample ID	Pass/fail PRRT	Pass/fail IN
1	A1	1012-6796-3642-892	♠ Failed	⚠ Failed
2	A2	1012-6796-3642-895	✓ Passed	✓ Passed
3	A3	1012-6796-3642-898	✓ Passed	✓ Passed
4	A4	1012-6796-3642-901	✓ Passed	⚠ Failed
5	D1N	1012-6796-3642-904	✓ Passed	✓ Passed
6	S1	1012-6796-3642-907	✓ Passed	N/A
7	S2	1012-6796-3642-909	✓ Passed	N/A

1.2 - Controls overview

	Control name	Exatype control ID	Region	Control status
1	V1cntrl_POS_IN	1012-6796-3642-911	IN	✓ Passed
2	V1cntrl_POS_PRRT	1012-6796-3642-913	PRRT	✓ Passed

Exatype job ID: 1012-6796-3642-890

Part 2 - Quality control

2.1 - Sequencing controls

Plate name: Plate 1
Sample name: V1cntrl_POS_IN
Sample ID: 1012-6796-3642-911
Plate ID: 1012-6796-3642-891

Sample type: Positive

Region: **IN**Status: **Passed**

Locus	Position	Amino acid	Status
IN	61	*	Present
IN	74	М	Present
IN	138	K	Present
IN	140	S	Present
IN	148	K	Present
IN	156	*	Present
IN	263	K	Present

Plate name: Plate 1
Sample name: V1cntrl_POS_PRRT
Sample ID: 1012-6796-3642-913
Plate ID: 1012-6796-3642-891
Sample type: Positive
Region: PRRT
Status: Passed

Locus	Position	Amino acid	Status
PR	37	S	Present
PR	41	*	Present
PR	54	М	Present
PR	90	М	Present
RT	41	L	Present
RT	65	R	Present
RT	68	*	Present
RT	103	N	Present
RT	122	E	Present
RT	181	С	Present
RT	183	*	Present
RT	184	V	Present
RT	214	L	Present

2.2 - Warnings

2.2.1 - Contamination checks

Samples too similar to positive control

None detected

Samples too similar to selected lab strains

None detected

Samples too similar to other samples from this job



S1

2.2.2 - Unusual mutation checks

Samples with excess APOBEC mutations

D1N

Samples with excess atypical mutations

D1N



Part 3 - Sample results

	Sample name	Exatype sample ID	Pass/fail PRRT	Pass/fail IN
1	A1	1012-6796-3642-892	♠ Failed	♠ Failed
2	A2	1012-6796-3642-895	✓ Passed	✓ Passed
3	A3	1012-6796-3642-898	✓ Passed	✓ Passed
4	A4	1012-6796-3642-901	✓ Passed	⚠ Failed
5	D1N	1012-6796-3642-904	✓ Passed	✓ Passed
6	S1	1012-6796-3642-907	✓ Passed	N/A
7	S2	1012-6796-3642-909	✓ Passed	N/A



Name: **A1** Analysis date: **2023-07-31** 10:44

Product: HIV (Sanger)

Sample status: Failed

Sequencing platform: CE

Assay: Thermo Fisher (with Integrase)

Exatype job ID: 1012-6796-3642-890



Sequencing platform: CE

HIV DRUG-RESISTANCE REPORT

Name: A2 (Summary result)

Analysis date: 2023-07-31 10:44

Product: HIV (Sanger)

Exatype version: 3.8.1.3

Assay: Thermo Fisher (with Integrase)

Resistance algorithm: Stanford HIVDB v9.4.1

Sample status: Completed

Susceptible Intermediate	resistance	•	High-level resistance No data
DRUG CLASS	DRUG	CALL ¹	MUTATIONS
	ATV/r	S	
	DRV/r	S	
	FPV/r	S	
PI	IDV/r	S	
	LPV/r	S	
	NFV	S	
	SQV/r	S	
	TPV/r	S	
	3ТС	S	
	ABC	S	
	AZT	S	
NRTI	D4T	S	
	DDI	S	
	FTC	S	
	TDF	S	
	DOR*	S	
	EFV*	S	
NNRTI	ETR	S	[RT] V106I
	NVP*	S	
	RPV	S	
	BIC	S	
	CAB	S	
INSTI	DTG	S	
	EVG	S	
	RAL	S	

 $^{^1}$ For Research Use Only. Not for use in diagnostic procedures. For more information please view our terms and conditions at https://exatype.com/terms-of-use or contact us at support@hyraxbio.com

^{*}The assay does not cover the entire reverse transcriptase gene region. Therefore, two potential drug-resistance scoring mutations - amino acid position 318 (scoring for DOR, EFV, and NVP) and position 348 (scoring for NVP) - are excluded from the drug-resistance interpretation.

[†]Mixed mutation



Name: A2 (Detailed result) Analysis date: 2023-07-31 10:44

Product: HIV (Sanger) Sample status: Completed

Sequencing platform: CE Exatype version: 3.8.1.3

Assay: Thermo Fisher (with Integrase) Resistance algorithm: Stanford HIVDB v9.4.1

Susceptible	 Potential low-level resistance 	 Low-level resistance
 Intermediate resistance 	High-level resistance	No data

DRUG CLASS	DRUG	CALL ¹	MUTATIONS
	ATV/r	S	
	DRV/r	S	
	FPV/r	S	
PI	IDV/r	S	
FI	LPV/r	S	
	NFV	S	
	SQV/r	S	
	TPV/r	S	
	3ТС	S	
	ABC	S	
	AZT	S	
NRTI	D4T	S	
	DDI	S	
	FTC	S	
	TDF	S	
	DOR*	P L-L	
	EFV*	S	
NNRTI	ETR	P L-L	[RT] V106I
	NVP*	P L-L	
	RPV	P L-L	
	BIC	S	
	CAB	S	
INSTI	DTG	S	
	EVG	S	
	RAL	S	

¹ For Research Use Only. Not for use in diagnostic procedures. For more information please view our terms and conditions at

https://exatype.com/terms-of-use or contact us at support@hyraxbio.com

*The assay does not cover the entire reverse transcriptase gene region. Therefore, two potential drug-resistance scoring mutations - amino acid position 318 (scoring for DOR, EFV, and NVP) and position 348 (scoring for NVP) - are excluded from the drug-resistance in the graph of the interpretation.

[†]Mixed mutation



Name: A2 (Mutations summary)

Analysis date: 2023-07-31 10:44

Product: HIV (Sanger)

Sample status: Completed

Sequencing platform: CE Exatype version: 3.8.1.3

Assay: Thermo Fisher (with Integrase)

Resistance algorithm: Stanford HIVDB v9.4.1

Mutations summary

PR Region

PI Major: None PI Accessory: None

PR Other: I13V, G16E, E35D, M36I, R41K, D60E, Q61D, L63T, H69K, L89IM[†]

RT Region

NRTI: None NNRTI: V106I

RT Other: P4S, K11T, V35T, T39GR[†], T107S, K122E, D123G, A158AS[†], D177E, I178IM[†], L193F, I195L, Q197K, T200A, Q207A, R211K, F227Y, I244V, V245T, E248T

IN Region

INSTI Major: None INSTI Accessory: None

IN Other: E11Q, K14R, S17N, V31I, I72V, I84M, L101I, T112V, I113V, S119P, T124A, T125A, G134D, H171*Q[†], Y194YC[†], G197GE[†], E198EK[†], V201I, T218L, N222K, L234I, D256E, A265V, S283G, R284G

†Mixed mutation



Name: A3 (Summary result)

Analysis date: 2023-07-31 10:44

Product: HIV (Sanger)

Sample status: Completed

Sequencing platform: CE Exatype version: 3.8.1.3

Assay: Thermo Fisher (with Integrase)

Resistance algorithm: Stanford HIVDB v9.4.1

Susceptible Intermediate r	esistance	•	High-level resistance No data
DRUG CLASS	DRUG	CALL ¹	MUTATIONS
	ATV/r	S	
	DRV/r	S	
	FPV/r	S	
PI	IDV/r	S	- [PR] V11IT [†]
	LPV/r	S	[1.1] 1221
	NFV	S	
	SQV/r	S	
	TPV/r	S	
	3ТС	S	
	ABC	S	
	AZT	S	
NRTI	D4T	S	
	DDI	S	
	FTC	S	
	TDF	S	
	DOR*	S	
	EFV*	R	
NNRTI	ETR	S	[RT] K103N
	NVP*	R	
	RPV	S	
	BIC	S	
	CAB	S	
INSTI	DTG	S	
	EVG	S	
	RAL	S	

 $^{^1}$ For Research Use Only. Not for use in diagnostic procedures. For more information please view our terms and conditions at https://exatype.com/terms-of-use or contact us at support@hyraxbio.com

^{*}The assay does not cover the entire reverse transcriptase gene region. Therefore, two potential drug-resistance scoring mutations - amino acid position 318 (scoring for DOR, EFV, and NVP) and position 348 (scoring for NVP) - are excluded from the drug-resistance interpretation.

[†]Mixed mutation



Name: A3 (Detailed result) Analysis date: 2023-07-31 10:44

Product: HIV (Sanger) Sample status: Completed Sequencing platform: CE Exatype version: 3.8.1.3

Assay: Thermo Fisher (with Integrase) Resistance algorithm: Stanford HIVDB v9.4.1

Susceptible	 Potential low-level resistance 	 Low-level resistance
 Intermediate resistance 	High-level resistance	No data

DRUG CLASS	DRUG	CALL ¹	MUTATIONS
	ATV/r	S	
	DRV/r	S	
	FPV/r	S	
PI	IDV/r	S	[PR] V11IT [†]
PI	LPV/r	S	[FK] VIIII
	NFV	S	
	SQV/r	S	
	TPV/r	S	
	3ТС	S	
	ABC	S	
	AZT	S	
NRTI	D4T	S	
	DDI	S	
	FTC	S	
	TDF	S	
	DOR*	S	
	EFV*	R	
NNRTI	ETR	S	[RT] K103N
	NVP*	R	
	RPV	S	
	BIC	S	
	CAB	S	
INSTI	DTG	S	
	EVG	S	
	RAL	S	

¹ For Research Use Only. Not for use in diagnostic procedures. For more information please view our terms and conditions at

https://exatype.com/terms-of-use or contact us at support@hyraxbio.com

*The assay does not cover the entire reverse transcriptase gene region. Therefore, two potential drug-resistance scoring mutations - amino acid position 318 (scoring for DOR, EFV, and NVP) and position 348 (scoring for NVP) - are excluded from the drug-resistance in the graph of the interpretation.

[†]Mixed mutation



Name: A3 (Mutations summary)

Analysis date: 2023-07-31 10:44

Product: HIV (Sanger)

Sample status: Completed

Sequencing platform: CE Exatype version: 3.8.1.3

Assay: Thermo Fisher (with Integrase)

Resistance algorithm: Stanford HIVDB v9.4.1

Mutations summary

PR Region

PI Major: None PI Accessory: None

PR Other: L10M, V11IT[†], T12TI[†], I13V, K14KR[†], I15IV[†], K20I, E35N, M36I, R41K, H69K, L89M, F99FL[†]

RT Region

NRTI: None NNRTI: K103N

 $\textbf{RT Other:} \ P4T, \ K11T, \ V35T, \ T39N, \ E40D, \ K43KR^{\dagger}, \ K49KR^{\dagger}, \ V60I, \ K102Q, \ D121H, \ K122E, \ K173R, \ Q174K, \ D177E, \ T200A, \ Q207E, \ R211K, \ V245K, \ D250E, \ V245K, \ D250E, \ V245K, \ V24$

IN Region

INSTI Major: None INSTI Accessory: None

IN Other: E11D, R20K, S24N, L101I, T124A, T125A, G134N, I135V, K136T, D167E, Y194YC[†], G197GE[†], E198EK[†], V201I, T206S, I208IM[†], L234I, S283G

†Mixed mutation



Name: A4 (Summary result)

Analysis date: 2023-07-31 10:44

Product: HIV (Sanger)

Sample status: Discordant

Sequencing platform: CE Exatype version: 3.8.1.3

Assay: Thermo Fisher (with Integrase)

Resistance algorithm: Stanford HIVDB v9.4.1

Susceptible Intermediate re	esistance	•	High-level resistance No data
DRUG CLASS	DRUG	CALL ¹	MUTATIONS
	ATV/r	S	
	DRV/r	S	
	FPV/r	S	
PI	IDV/r	S	
	LPV/r	S	
	NFV	S	
	SQV/r	S	
	TPV/r	S	
	3ТС	S	
	ABC	S	
	AZT	S	
NRTI	D4T	S	
	DDI	S	
	FTC	S	
	TDF	S	
	DOR*	S	
	EFV*	S	
NNRTI	ETR	S	
	NVP*	S	
	RPV	S	
	BIC	No data	
	CAB	No data	
INSTI	DTG	No data	
	EVG	No data	
	RAL	No data	

 $^{^1}$ For Research Use Only. Not for use in diagnostic procedures. For more information please view our terms and conditions at https://exatype.com/terms-of-use or contact us at support@hyraxbio.com

^{*}The assay does not cover the entire reverse transcriptase gene region. Therefore, two potential drug-resistance scoring mutations - amino acid position 318 (scoring for DOR, EFV, and NVP) and position 348 (scoring for NVP) - are excluded from the drug-resistance interpretation.

[†]Mixed mutation



Name: A4 (Detailed result) Analysis date: 2023-07-31 10:44

Product: HIV (Sanger) Sample status: Discordant

Sequencing platform: CE Exatype version: 3.8.1.3

Assay: Thermo Fisher (with Integrase) Resistance algorithm: Stanford HIVDB v9.4.1

Susceptible	 Potential low-level resistance 	 Low-level resistance
 Intermediate resistance 	High-level resistance	No data

DRUG CLASS	DRUG	CALL ¹	MUTATIONS
	ATV/r	S	
	DRV/r	S	
	FPV/r	S	
PI	IDV/r	S	
PI	LPV/r	S	
	NFV	S	
	SQV/r	S	
	TPV/r	S	
	3ТС	S	
	ABC	S	
	AZT	S	
NRTI	D4T	S	
	DDI	S	
	FTC	S	
	TDF	S	
	DOR*	S	
	EFV*	S	
NNRTI	ETR	S	
	NVP*	S	
	RPV	S	
	BIC	No data	
	CAB	No data	
INSTI	DTG	No data	
	EVG	No data	
	RAL	No data	

¹ For Research Use Only. Not for use in diagnostic procedures. For more information please view our terms and conditions at

https://exatype.com/terms-of-use or contact us at support@hyraxbio.com

*The assay does not cover the entire reverse transcriptase gene region. Therefore, two potential drug-resistance scoring mutations - amino acid position 318 (scoring for DOR, EFV, and NVP) and position 348 (scoring for NVP) - are excluded from the drug-resistance in the graph of the interpretation.

[†]Mixed mutation



Sequencing platform: CE

HIV DRUG-RESISTANCE REPORT

Name: A4 (Mutations summary)

Analysis date: 2023-07-31 10:44

Product: HIV (Sanger)

Sample status: Discordant

Exatype version: 3.8.1.3

Assay: Thermo Fisher (with Integrase)

Resistance algorithm: Stanford HIVDB v9.4.1

Mutations summary

PR Region

PI Major: None PI Accessory: None

PR Other: R57RK[†], I62IV[†], L63AP[†], I64IM[†], V77I

RT Region

NRTI: None NNRTI: None

RT Other: D123E, I178M, Q207E, R211K

IN Region

INSTI Major: None INSTI Accessory: None IN Other: None

†Mixed mutation



Name: D1N (Summary result)

Analysis date: 2023-07-31 10:44

Product: **HIV (Sanger)**Sequencing platform: **CE**

Exatype version: 3.8.1.3

Sample status: Completed

Assay: Thermo Fisher (with Integrase)

Resistance algorithm: Stanford HIVDB v9.4.1

Susceptible Intermediate resistance High-level resistance				
DRUG CLASS	DRUG	CALL ¹	MUTATIONS	
	ATV/r	- 1		
	DRV/r	S		
	FPV/r	I		
PI	IDV/r	I	[PR] D30N, [PR] M46I, [PR] G48S,	
PI	LPV/r	I	[PR] G73S	
	NFV	R		
	SQV/r	R		
	TPV/r	S		
	ЗТС	R		
	ABC	I		
	AZT	I		
NRTI	D4T	I	[RT] M41L, [RT] D67N, [RT] L74I, [RT] M184I, [RT] T215C	
	DDI	R		
	FTC	R		
	TDF	S		
	DOR*	R		
	EFV*	R	[RT] L100V, [RT] K101H, [RT] K103N,	
NNRTI	ETR	R	[RT] V106I, [RT] V108I, [RT] E138A, [RT] V179F, [RT] Y181C, [RT] M184I,	
	NVP*	R	[RT] G190E, [RT] F227FL [†] , [RT] M230I	
	RPV	R		
	BIC	I		
	CAB	- 1		
INSTI	DTG	- 1	[IN] G163R, [IN] D232N, [IN] R263K	
	EVG	- 1		
	RAL	- 1		

 $^{^1}$ For Research Use Only. Not for use in diagnostic procedures. For more information please view our terms and conditions at https://exatype.com/terms-of-use or contact us at support@hyraxbio.com

^{*}The assay does not cover the entire reverse transcriptase gene region. Therefore, two potential drug-resistance scoring mutations - amino acid position 318 (scoring for DOR, EFV, and NVP) and position 348 (scoring for NVP) - are excluded from the drug-resistance interpretation.

[†]Mixed mutation



Name: D1N (Detailed result) Analysis date: 2023-07-31 10:44

Product: HIV (Sanger) Sample status: Completed Sequencing platform: CE Exatype version: 3.8.1.3

Assay: Thermo Fisher (with Integrase) Resistance algorithm: Stanford HIVDB v9.4.1

Susceptible	 Potential low-level resistance 	Low-level resistance
 Intermediate resistance 	High-level resistance	No data

DRUG CLASS	DRUG	CALL ¹	MUTATIONS	
	ATV/r	I		
	DRV/r	S		
	FPV/r	L-L		
PI	IDV/r	- I	[PR] D30N, [PR] M46I, [PR] G48S,	
FI	LPV/r	L-L	[PR] G73S	
	NFV	R		
	SQV/r	R		
	TPV/r	S		
	3ТС	R		
	ABC	I		
	AZT	- 1	RT] M41L, [RT] D67N, [RT] L74I,	
NRTI	D4T	- I	[RT] M41L, [RT] D57N, [RT] L741,	
	DDI	R		
	FTC	R		
	TDF	S		
	DOR*	R	[DT] 1400V [DT] 1/404U [DT] 1/400V	
	EFV*	R	[RT] L100V, [RT] K101H, [RT] K103N, [RT] V106I, [RT] V108I, [RT] E138A,	
NNRTI	ETR	R	[RT] V179F, [RT] Y181C, [RT] M184I,	
	NVP*	R	[RT] G190E, [RT] F227FL [†] , [RT] M230I	
	RPV	R		
	BIC	- 1		
	CAB	- 1		
INSTI	DTG	- I	[IN] G163R, [IN] D232N, [IN] R263K	
	EVG	- 1		
	RAL	I		

¹ For Research Use Only. Not for use in diagnostic procedures. For more information please view our terms and conditions at

https://exatype.com/terms-of-use or contact us at support@hyraxbio.com

*The assay does not cover the entire reverse transcriptase gene region. Therefore, two potential drug-resistance scoring mutations - amino acid position 318 (scoring for DOR, EFV, and NVP) and position 348 (scoring for NVP) - are excluded from the drug-resistance in the graph of the interpretation.

[†]Mixed mutation



Name: D1N (Mutations summary) Analysis date: 2023-07-31 10:44

Product: HIV (Sanger) Sample status: Completed

Sequencing platform: CE Exatype version: 3.8.1.3

Assay: Thermo Fisher (with Integrase) Resistance algorithm: Stanford HIVDB v9.4.1

Mutations summary

PR Region

PI Major: D30N, M46I, G48S

PI Accessory: G73S

PR Other: M36MI[†], R41RK[†], L63P, I64V, E65D, K70R, I72V, V77I

NRTI: M41L, D67N, L74I, M184I, T215C

NNRTI: L100V, K101H, K103N, V106I, V108I, E138A, V179F, Y181C, Y188S, G190E, F227FL[†], M230I RT Other: V35M, Q174QR[†], D177E, D186C, E203EK[†], Q207E, L210H, R211K, G213H, D218L, K223KE[†], L228LR[†], V245K, D250E

IN Region

INSTI Major: R263K

INSTI Accessory: G163R, D232N

IN Other: L2Y, I5M, E10K, E11K, W19W*[†], I72V, S123G, T124A, K127R, K264R, G277S

[†]Mixed mutation



Name: S1 (Summary result)

Analysis date: 2023-07-31 10:44

Product: HIV (Sanger)

Sequencing platform: CE

Exatype version: 3.8.1.3

Assay: Thermo Fisher (with Integrase)

Resistance algorithm: Stanford HIVDB v9.4.1

Susceptible			High-level resistance No data	
DRUG CLASS	DRUG	CALL ¹	MUTATIONS	
	ATV/r	R		
	DRV/r	S		
	FPV/r	1		
PI	IDV/r	R	[PR] M46I, [PR] F53L, [PR] I54V,	
	LPV/r	R	[PR] V82A	
	NFV	R		
	SQV/r	R		
	TPV/r	1		
	3ТС	R		
	ABC	R		
	AZT	R	[RT] M41L,[RT] E44D,[RT] D67N,	
NRTI	D4T	R	[RT] T69D,[RT] M184V,[RT] L210W,	
	DDI	R	[RT] T215Y	
	FTC	R		
	TDF	R		
	DOR*	- 1		
	EFV*	R		
NNRTI	ETR	- 1	[RT] A98G, [RT] G190A	
	NVP*	R		
	RPV	- 1		
	BIC	No data		
INSTI	CAB	No data		
	DTG	No data		
	EVG	No data		
	RAL	No data		

 $^{^1}$ For Research Use Only. Not for use in diagnostic procedures. For more information please view our terms and conditions at https://exatype.com/terms-of-use or contact us at support@hyraxbio.com

^{*}The assay does not cover the entire reverse transcriptase gene region. Therefore, two potential drug-resistance scoring mutations - amino acid position 318 (scoring for DOR, EFV, and NVP) and position 348 (scoring for NVP) - are excluded from the drug-resistance interpretation.

[†]Mixed mutation



Name: S1 (Detailed result) Analysis date: 2023-07-31 10:44

Product: HIV (Sanger) Sample status: Completed

Sequencing platform: CE Exatype version: 3.8.1.3

Assay: Thermo Fisher (with Integrase) Resistance algorithm: Stanford HIVDB v9.4.1

Susceptible	 Potential low-level resistance 	 Low-level resistance
 Intermediate resistance 	High-level resistance	No data

DRUG CLASS	DRUG	CALL ¹	MUTATIONS	
	ATV/r	R		
	DRV/r	S		
	FPV/r	- 1		
PI	IDV/r	R	[PR] M46I, [PR] F53L, [PR] I54V,	
PI	LPV/r	R	[PR] V82A	
	NFV	R		
	SQV/r	R		
	TPV/r	L-L		
	3ТС	R		
	ABC	R		
NRTI	AZT	R	[RT] M41L,[RT] E44D,[RT] D67N,	
	D4T	R	[RT] T69D,[RT] M184V,[RT] L210W,	
	DDI	R	[RT] T215Y	
	FTC	R		
	TDF	R		
	DOR*	L-L		
	EFV*	R		
NNRTI	ETR	L-L	[RT] A98G, [RT] G190A	
	NVP*	R		
	RPV	I		
INSTI	BIC	No data		
	CAB	No data		
	DTG	No data		
	EVG	No data		
	RAL	No data		

roi Researcii Use Uniy. Not for use in diagnostic procedures. For more information please view our terms and conditions at https://exatype.com/terms-of-use or contact us at support@hyraxbio.com

*The assay does not cover the entire reverse transcriptase gene region. Therefore, two potential drug-resistance scoring mutations - amino acid position 318 (scoring for DOR, EFV, and NVP) and position 348 (scoring for NVP) - are excluded from the drug-resistance interpretation.

[†]Mixed mutation



Name: S1 (Mutations summary)

Analysis date: 2023-07-31 10:44

Product: HIV (Sanger)

Sample status: Completed

Sequencing platform: CE Exatype version: 3.8.1.3

Assay: Thermo Fisher (with Integrase)

Resistance algorithm: Stanford HIVDB v9.4.1

Mutations summary

PR Region

PI Major: M46I, I54V, V82A

PI Accessory: F53L

PR Other: L10I, I13V, G16E, E35D, M36I, N37D, R41K, R57K, L63S, H69K, K70R, L89M

RT Region

NRTI: M41L, E44D, D67N, T69D, M184V, L210W, T215Y

NNRTI: A98G, G190A

RT Other: V35T, V60I, V111I, K122E, D123S, I135T, K173AT[†], Q174K, V179I, T200A, I202V, E203K, Q207D, H208Y, R211N, V245Q, D250E

IN Region

INSTI Major: None INSTI Accessory: None IN Other: None

†Mixed mutation



Name: S2 (Summary result)

Analysis date: 2023-07-31 10:44

Product: HIV (Sanger)

Sample status: Completed

Sequencing platform: CE Exatype version: 3.8.1.3

Assay: Thermo Fisher (with Integrase)

Resistance algorithm: Stanford HIVDB v9.4.1

Susceptible Intermediate r	esistance	•	High-level resistance No data	
DRUG CLASS	DRUG	CALL ¹	MUTATIONS	
	ATV/r	I		
	DRV/r	S		
	FPV/r	1		
PI	IDV/r	- 1	[PR] M46I, [PR] F53L, [PR] V82A	
	LPV/r	- 1	[,, [,, [,]	
	NFV	R		
	SQV/r	- 1		
	TPV/r	S		
	3ТС	R		
	ABC	R		
	AZT	R	[RT] M41L,[RT] E44D,[RT] D67N,	
NRTI	D4T	R	[RT] T69D, [RT] M184V, [RT] L210W,	
	DDI	R	[RT] T215Y	
	FTC	R		
	TDF	R		
	DOR*	1		
	EFV*	R		
NNRTI	ETR	1	[RT] A98G, [RT] G190A	
	NVP*	R		
	RPV	I		
INSTI	BIC	No data		
	CAB	No data		
	DTG	No data		
	EVG	No data		
	RAL	No data		

 $^{^1}$ For Research Use Only. Not for use in diagnostic procedures. For more information please view our terms and conditions at https://exatype.com/terms-of-use or contact us at support@hyraxbio.com

^{*}The assay does not cover the entire reverse transcriptase gene region. Therefore, two potential drug-resistance scoring mutations - amino acid position 318 (scoring for DOR, EFV, and NVP) and position 348 (scoring for NVP) - are excluded from the drug-resistance interpretation.



Name: S2 (Detailed result) Analysis date: 2023-07-31 10:44

Product: HIV (Sanger) Sample status: Completed

Sequencing platform: CE Exatype version: 3.8.1.3

Assay: Thermo Fisher (with Integrase) Resistance algorithm: Stanford HIVDB v9.4.1

Susceptible	 Potential low-level resistance 	 Low-level resistance
 Intermediate resistance 	High-level resistance	No data

DRUG CLASS	DRUG	CALL ¹	MUTATIONS	
	ATV/r	I		
	DRV/r	S		
	FPV/r	I		
PI	IDV/r	I	[PR] M46I,[PR] F53L,[PR] V82A	
	LPV/r	I	[11] 1110, [11] 1302, [11] 1027	
	NFV	R		
	SQV/r	I		
	TPV/r	S		
	ЗТС	R		
	ABC	R		
NRTI	AZT	R	[RT] M41L, [RT] E44D, [RT] D67N,	
	D4T	R	[RT] T69D,[RT] M184V,[RT] L210W,	
	DDI	R	[RT] T215Y	
	FTC	R		
	TDF	R		
	DOR*	L-L		
	EFV*	R		
NNRTI	ETR	L-L	[RT] A98G, [RT] G190A	
	NVP*	R		
	RPV	I		
	BIC	No data		
INSTI	CAB	No data		
	DTG	No data		
	EVG	No data		
	RAL	No data		

roi Researcii Use Uniy. Not for use in diagnostic procedures. For more information please view our terms and conditions at https://exatype.com/terms-of-use or contact us at support@hyraxbio.com

*The assay does not cover the entire reverse transcriptase gene region. Therefore, two potential drug-resistance scoring mutations - amino acid position 318 (scoring for DOR, EFV, and NVP) and position 348 (scoring for NVP) - are excluded from the drug-resistance interpretation.



Name: S2 (Mutations summary)

Analysis date: 2023-07-31 10:44

Product: HIV (Sanger)

Sample status: Completed

Sequencing platform: CE Exatype version: 3.8.1.3

Assay: Thermo Fisher (with Integrase)

Resistance algorithm: Stanford HIVDB v9.4.1

Mutations summary

PR Region

PI Major: M46I, V82A PI Accessory: F53L

PR Other: L10I, I13V, G16E, E35D, M36I, N37D, R41K, R57K, L63S, H69K, K70R, L89M

RT Region

NRTI: M41L, E44D, D67N, T69D, M184V, L210W, T215Y

NNRTI: A98G, G190A

RT Other: V35T, V60I, V111I, K122E, D123S, I135T, K173T, Q174K, V179I, T200A, I202V, E203K, R206K, Q207D, H208Y, R211N, V245Q, D250E

IN Region

INSTI Major: None INSTI Accessory: None IN Other: None

Exatype job ID: 1012-6796-3642-890